



Supporting Information

for

Total synthesis of decarboxyaltenusin

Lucas Warmuth, Aaron Weiß, Marco Reinhardt, Anna Meschkov, Ute Schepers
and Joachim Podlech

Beilstein J. Org. Chem. **2021**, *17*, 224–228. [doi:10.3762/bjoc.17.22](https://doi.org/10.3762/bjoc.17.22)

Experimental procedures and NMR spectra of all new compounds and of decarboxyaltenusin (1)

Table of contents

A. Experimental procedures

General

- 1,2-Bis(*tert*-butyldimethylsilyloxy)-4-methylbenzene (**3**)
 - 1-Bromo-3,4-bis(*tert*-butyldimethylsilyloxy)-6-methylbenzene (**5a**)
 - 2-[4,5-Bis(*tert*-butyldimethylsilyloxy)-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**6a**)
 - 3-Bromo-5-methoxyphenol (**8**)
 - 1-Bromo-3-(*tert*-butyldimethylsilyloxy)-5-methoxybenzene (**9a**)
 - 3',4,5-Tris(*tert*-butyldimethylsilyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (**10a**)
 - 4-Bromo-5-methylbenzene-1,2-diol (**4**)
 - 4,5-Dibenzyloxy-1-bromo-2-methylbenzene (**5b**)
 - 2-(4,5-Dibenzyloxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**6b**)
 - 1-(Benzyloxy)-3-bromo-5-methoxybenzene (**9b**)
 - 3',4,5-Tris(benzyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (**10b**)
 - 5'-Methoxy-6-methyl-[1,1'-biphenyl]-3,3',4-triol; Decarboxyaltenusin (**1**)
- Cell Culture and Cytotoxicity Studies

B. NMR spectra

- 1. 1-Bromo-3,4-bis(*tert*-butyldimethylsilyloxy)-6-methylbenzene (5a)**
 - ¹H NMR (400 MHz, CDCl₃)
 - ¹³C NMR (100 MHz, CDCl₃)
- 2. 2-[4,5-Bis(*tert*-butyldimethylsilyloxy)-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6a)**
 - ¹H NMR (400 MHz, CDCl₃)
 - ¹³C NMR (100 MHz, CDCl₃)
- 3. 1-Bromo-3-(*tert*-butyldimethylsilyloxy)-5-methoxybenzene (9a)**
 - ¹H NMR (400 MHz, CDCl₃)
 - ¹³C NMR (100 MHz, CDCl₃)
- 4. 3',4,5-Tris(*tert*-butyldimethylsilyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10a)**
 - ¹H NMR (400 MHz, CDCl₃)
 - ¹³C NMR (400 MHz, CDCl₃)
- 5. 4,5-Dibenzyloxy-1-bromo-2-methylbenzene (5b)**
 - ¹H NMR (400 MHz, CDCl₃)
 - ¹³C NMR (100 MHz, CDCl₃)

6. 2-(4,5-Dibenzyloxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6b)

¹H NMR (400 MHz, CDCl₃)

¹³C NMR (100 MHz, CDCl₃)

7. 1-(Benzyloxy)-3-bromo-5-methoxybenzene (9b)

¹H NMR (400 MHz, CDCl₃)

¹³C NMR (100 MHz, CDCl₃)

8. 3',4,5-Tris(benzyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10b)

¹H NMR (400 MHz, CDCl₃)

¹³C NMR (100 MHz, CDCl₃)

9. 5'-Methoxy-6-methyl-[1,1'-biphenyl]-3,3',4-triol; decarboxyaltenusin (1)

¹H NMR (400 MHz, DMSO-*d*₆)

¹³C NMR (100 MHz, DMSO-*d*₆)

HSQC (100 MHz, DMSO-*d*₆)

COSY (100 MHz, DMSO-*d*₆)

HMBC (100 MHz, DMSO-*d*₆)

A. Experimental procedures

General

THF and dioxane were distilled from sodium with benzophenone ketyl radical as indicator. All moisture-sensitive reactions were carried out under O₂-free argon using oven-dried glassware and a vacuum line. Flash column chromatography [1] was carried out using Merck SiO₂ 60 (230–400 mesh) and thin layer chromatography (TLC) was carried out using commercially available Merck F₂₅₄ pre-coated sheets. ¹H and ¹³C NMR spectra were recorded with Bruker Avance 300, 400, or 600 instruments. Chemical shifts are given in ppm and are referenced by using the residual signals of the solvent as internal standard. IR spectra were recorded with a Bruker Alpha spectrometer and mass spectra were recorded with a Finnigan MAT-95 mass spectrometer.

1,2-Bis(tert-butyl dimethylsilyloxy)-4-methylbenzene (3)

According to a published procedure [2] DMAP (600 mg, 4.91 mmol), imidazole (13.3 g, 196 mmol), and *t*-BuMe₂SiCl (16.7 g, 111 mmol) were added to a solution of 4-methylbenzene-1,2-diol (**2**, 5.17 g, 41.6 mmol) in DMF (150 mL) and the mixture was stirred for 4 h at 50 °C. Then, a saturated aqueous NaHCO₃ solution (200 mL) was added and the mixture was extracted with Et₂O (4 × 200 mL). The combined organic layers were washed with aqueous HCl solution (1 M, 100 mL), dried (Na₂SO₄), and concentrated at reduced pressure to yield **3** as a yellowish oil (14.2 g, 40.3 mmol, 96%). ¹H NMR (300 MHz, CDCl₃): δ (ppm) = 0.21 (s, 6 H, SiMe₂), 0.22, (s, 6 H, SiMe₂), 1.01 (s, 9 H, Si*t*Bu), 1.02 (s, 9 H, Si*t*Bu), 2.25 (s, 3 H, ArMe), 6.64 (m, 2 H, 2×ArH), 6.74 (d, ³J = 8.0 Hz, 1 H, ArH). These NMR data are in agreement with published data [2].

-
1. Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923–2925.
 2. Berkowitz, D. B.; Smith, M. K. *J. Org. Chem.* **1995**, *60*, 1233–1238.

1-Bromo-3,4-bis(tert-butyldimethylsilyloxy)-6-methylbenzene (5a)

In analogy to a published procedure [3] a solution of NBS (4.14 g, 23.3 mmol) in MeCN (60 mL) was added at 0 °C to a solution of protected catechol **3** (7.71 g, 21.9 mmol) in MeCN (75 mL) and stirring was continued for 72 h at room temperature. Then, H₂O (200 mL) was added and the mixture was extracted with hexanes (3 × 100 mL). The combined organic layers were dried (Na₂SO₄) and concentrated at reduced pressure to yield **5a** as a red oil (9.09 g, 21.1 mmol, 96%). ¹H NMR (400 MHz, CDCl₃): δ (ppm) = 0.19 (s, 6 H, SiMe₂), 0.20 (s, 6 H, SiMe₂), 0.99 (s, 18 H, 2×Si*t*Bu), 2.26 (s, 3 H, ArMe), 6.70 (s, 1 H, ArH), 6.95 (s, 1 H, ArH); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) = -4.03 (SiMe), -3.98 (SiMe), 18.6 (C), 22.3 (CH₃), 26.1 (CH₃), 115.0 (C), 123.1 (CH), 124.6 (CH), 130.5 (C), 145.7 (C), 146.2 (C), signals partly covered; IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2928 (w), 2858 (w), 1495 (m), 1305 (m), 1253 (m), 994 (w), 910 (m), 836 (m), 780 (m); MS (EI, 140 °C): *m/z* (%) = 430 (4) [M⁺], 375 (10), 373 (9), 115 (38), 73 (100), 69 (13); HRMS (EI): found 430.1355. C₁₉H₃₅O₂⁷⁹Br²⁸Si₂ requires 430.1354.

2-[4,5-Bis(tert-butyldimethylsilyloxy)-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6a)

Bromide **5a** (5.00 g, 11.6 mmol) was dissolved under an argon atmosphere in THF (150 mL) and the solution was cooled to -78 °C. Then, *n*-BuLi (2.5M in hexanes, 7.00 mL, 17.5 mmol) was added via a syringe and the mixture was stirred for 45 min at that temperature. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.8 mL, 4.38 g, 23.5 mmol) was added and the temperature was raised to room temperature overnight. H₂O (500 mL) and brine (150 mL) were added and the organic layer was dried (Na₂SO₄), concentrated at reduced pressure, and purified by column chromatography (silica gel, cyclohexane/EtOAc 50:1, with 3% Et₃N) to yield **6a** as a yellowish, slowly solidifying oil (3.15 g, 6.57 mmol, 57%). *R*_f = 0.66

(cyclohexane/EtOAc 10:1); ^1H NMR (400 MHz, CDCl_3): δ (ppm) = 0.20 (s, 6 H, SiMe_2), 0.21 (s, 6 H, SiMe_2), 0.99 (s, 9 H, $\text{Si}t\text{Bu}$), 1.00 (s, 9 H, $\text{Si}t\text{Bu}$), 1.32 (s, 12 H, Me_2CCMe_2), 2.42 (s, 3 H, ArMe), 6.64 (s, 1 H, ArH), 7.24 (s, 1 H, ArH); ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) = -4.0 (SiCH_3), -3.9 (SiCH_3), 18.6 (C), 18.7 (C), 21.6 (CH_3), 25.0 (CH_3), 26.1 (CH_3), 26.2 (CH_3), 83.2 (C), 123.0 (CH), 128.7 (CH), 138.8 (C), 144.0 (C), 149.1 (C); IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 2928 (m), 2858 (w), 1504 (m), 1471 (w), 1397 (m), 1334 (m), 1305 (m), 1249 (m), 1142 (m), 835 (s), 778 (s); MS (EI, 90 °C): m/z (%) = 479 (12), 478 (38) [M^+], 477 (8), 322 (62), 321 (100), 320 (52), 231 (24), 181 (100), 131 (100), 100 (27), 73 (100); HRMS (EI): found 478.3100. $\text{C}_{25}\text{H}_{47}\text{O}_4^{11}\text{B}^{28}\text{Si}_2$ requires 478.3101.

3-Bromo-5-methoxyphenol (8)

In slight variation of a published protocol [4] 1-bromo-3,5-dimethoxybenzene (4.23 g, 19.4 mmol) was dissolved under an argon atmosphere in CH_2Cl_2 (30 mL) and cooled to -78 °C. BBr_3 (1 M in CH_2Cl_2 , 17 mL, 17.0 mmol) was added dropwise and the mixture was stirred for 18 h while the temperature raised to room temperature. Then, H_2O (40 mL) was added slowly at -78 °C and the mixture was again warmed to room temperature and stirring was continued until clearing of the phases. The aqueous layer was extracted with Et_2O (2×50 mL) and the combined organic layers were washed with saturated NaHCO_3 solution, dried (MgSO_4), concentrated at reduced pressure, and purified by column chromatography (silica gel, cyclohexane/EtOAc 3:1 \rightarrow 1:1) to yield **8** (2.78 g, 13.7 mmol, 71%) and 5-bromoresorcinol (900 mg, 4.76 mmol, 25%) as colorless solids. **8**: R_f = 0.26 (cyclohexane/EtOAc 3:1); ^1H NMR (300 MHz, CDCl_3): δ (ppm) = 3.76 (s, 3 H, OMe), 5.01 (s, 1 H, OH), 6.33 (m, 1 H, ArH), 6.61, (m, 1 H, ArH), 6.66 (m, 1 H, ArH). These NMR data are in agreement with published data [4].

4. Lindgren, A. E. G.; Öberg, C. T.; Hillgren, J. M.; Eloffsson, M. *Eur. J. Org. Chem.* **2016**, 426–429.

5-Bromoresorcinol: $R_f = 0.08$ (hexanes/EtOAc 3:1); $^1\text{H NMR}$ (300 MHz, acetone- d_6): δ (ppm) = 6.33 (m, 1 H, 2-H), 6.52 (m, 2 H, 4-H, 6-H), 8.63 (s, 2 H, OH). These NMR data are in agreement with published data [5].

1-Bromo-3-(tert-butyldimethylsilyloxy)-5-methoxybenzene (9a)

t-BuMe₂SiCl (2.58 g, 17.1 mmol), DMAP (29.0 mg, 0.237 mmol), and imidazole (2.27 g, 33.3 mmol) were added successively to a solution of bromide **8** (2.08 g, 10.2 mmol) in DMF (50 mL). The mixture was stirred for 4 h at 55 °C and cooled to room temperature. Then, H₂O (40 mL) and saturated NaHCO₃ solution (50 mL) were added and the mixture was extracted with Et₂O (3 × 50 mL). The combined organic layers were dried (Na₂SO₄), concentrated at reduced pressure, and purified by column chromatography (silica gel, cyclohexane with 2.3% Et₃N) to yield **9a** as a colorless oil (2.37 g, 7.48 mmol, 73%). $R_f = 0.35$ (cyclohexane); $^1\text{H NMR}$ (400 MHz, CDCl₃): δ (ppm) = 0.20 (s, 6 H, SiMe₂), 0.97 (s, 9 H, Si*t*Bu), 3.75 (s, 3 H, OMe), 6.32 (t, $^4J = 2.2$ Hz, 1 H, Ar*H*), 6.61 (t, $^4J = 1.9$ Hz, 1 H, Ar*H*), 6.68 (t, $^4J = 1.9$ Hz, 1 H, Ar*H*); $^{13}\text{C NMR}$ (100 MHz, CDCl₃): δ (ppm) = -4.3 (SiMe₂), 18.3 (C), 25.7 (CH₃), 55.6 (CH₃), 105.7 (CH), 110.5 (CH), 116.3 (CH), 122.7 (C), 157.4 (C), 161.2 (C); IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2929 (w), 2856 (w), 1592 (m), 1566 (m), 1441 (m), 1424 (m), 1315 (w), 1288 (w), 1157 (m), 1051 (m), 809 (m), 780 (w); MS (EI, 70 °C): m/z (%) = 318 (26), 316 (25) [M⁺], 261 (98), 259 (100), 180 (67), 137 (38), 75 (42), 73 (99), 59 (49), 57 (41); HRMS (EI): found 316.0489. C₁₃H₂₁O₂⁷⁹Br²⁸Si requires 316.0488. No spectroscopic data for comparison were given in the literature for this known compound [6].

5. Wu, X.; Zhou, J.; Snider, B. B. *Angew. Chem.* **2009**, *121*, 1309–1312; *Angew. Chem. Int. Ed.* **2009**, *48*, 1283–1286.

6. Wada, Y.; Matsumoto, A.; Asano, K.; Matsubara, S. *RSC Adv.* **2019**, *9*, 31654–31658.

3',4,5-Tris(tert-butyl dimethylsilyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10a)

Boronate **6a** (2.42 g, 5.05 mmol), bromide **9a** (1.99 g, 6.27 mmol), Pd(OAc)₂ (40 mg, 0.18 mmol), SPhos (151 mg, 0.366 mmol), and Cs₂CO₃ (5.92 g, 18.1 mmol) were dissolved in a 500 mL Schlenk flask under an argon atmosphere in degassed dioxane/H₂O 7:1 (200 mL). The mixture was heated for 18 h at 70 °C, H₂O (300 mL) was added, and the mixture was extracted with EtOAc (4 × 100 mL). The combined organic layers were washed with brine (150 mL), dried (Na₂SO₄), concentrated at reduced pressure, and purified by column chromatography (silica gel, cyclohexane with 2.5% Et₃N) to yield a non-separable mixture of **10a** and a non-identified by-product (2.91 g, 4.95 mmol, 98%). *R*_f = 0.47 (cyclohexane); ¹H NMR (600 MHz, CDCl₃): δ (ppm) = 0.20 (s, 6 H, SiMe₂), 0.22 (s, 6 H, SiMe₂), 0.23 (s, 6 H, SiMe₂), 0.99 (s, 9 H, Si*t*Bu), 0.99 (s, 9 H, Si*t*Bu), 1.02 (s, 9 H, Si*t*Bu), 2.16 (s, 3 H, ArMe), 3.79 (s, 3 H, OMe), 6.36–6.39 (m, 2 H, ArH), 6.44 (s, 1, ArH), 6.69 (s, 1 H, ArH), 6.71 (s, 1 H, ArH); ¹³C NMR (150 MHz, CDCl₃): δ (ppm) = -4.2 (2×SiMe₂), -3.9 (SiMe₂), 18.4 (C), 18.6 (C), 18.6 (C), 20.0 (CH₃), 25.9 (CH₃), 26.1 (CH₃), 26.1 (CH₃), 55.4 (CH₃), 104.6 (CH), 108.4 (CH), 114.0 (CH), 122.4 (CH), 122.9 (CH), 128.1 (C), 134.9 (C), 143.8 (C), 144.4 (C), 145.9 (C), 156.4 (C), 160.3 (C); IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2928 (m), 2856 (w), 1590 (m), 1509 (m), 1290 (m), 1249 (m), 1192 (m), 1158 (m), 1051 (w), 833 (m), 775 (m); MS (EI, 150 °C): *m/z* (%) = 590 (3), 589 (8), 588 (15) [M⁺], 401 (16), 115 (13), 73 (100); HRMS (EI) found 588.3481. C₃₂H₅₆O₄²⁸Si₃ requires 588.3483.

4-Bromo-5-methylbenzene-1,2-diol (4)

In analogy to a published procedure [3] a solution of NBS (6.33 g, 35.6 mmol) in MeCN (85 mL) was added within 30 min to an ice-cooled solution of 4-methylbenzene-1,2-diol (**2**, 4.10 g, 33.0 mmol) in MeCN (100 mL). The resulting yellow mixture was stirred for 71 h at room temperature while it turned red. It was poured on H₂O (200 mL) and the mixture was extracted with EtOAc (3 × 300 mL). The combined organic layers were dried (Na₂SO₄) and

concentrated at reduced pressure to yield **4** as a brown solid (6.71 g, 33.0 mmol, quant.). $R_f = 0.65$ (cyclohexane/EtOAc 1:1); $^1\text{H NMR}$ (300 MHz, DMSO- d_6): δ (ppm) = 2.14 (s, 3 H, CH₃), 6.70 (s, 1 H, 3-H or 6-H), 6.88 (s, 1 H, 6-H or 3-H), 9.05 (s, 1 H, OH), 9.14 (s, 1 H, OH); $^{13}\text{C NMR}$ (75 MHz, DMSO- d_6): δ (ppm) = 21.5 (CH₃), 111.6 (CH), 117.8 (C), 118.6 (CH), 127.1 (C), 144.5 (C), 144.9 (C). The $^1\text{H NMR}$ data are in agreement with published data [3,7].

4,5-Dibenzyloxy-1-bromo-2-methylbenzene (5b)

In analogy to a published procedure [8] a mixture of brominated catechol **4** (2.17 g, 10.6 mmol), KI (136 mg, 0.82 mmol), K₂CO₃ (5.87 g, 42.5 mmol), and BnBr (2.53 mL, 3.64 g, 21.3 mmol) in DMF/acetone 1:2 (40 mL) under an argon atmosphere was stirred for 30 min at room temperature and for 29 h at 70 °C. Then, H₂O (20 mL) was added after cooling and the mixture was extracted with CHCl₃ (3 × 70 mL). The combined organic layers were washed with aqueous NaOH solution (5 M, 300 mL) and H₂O (2 × 50 mL), dried (MgSO₄), concentrated at reduced pressure, and purified by column chromatography (silica gel, hexane/EtOAc 6:1) to yield **5b** as a colorless solid (3.50 g, 9.14 mmol, 86%) and benzyloxy-4-bromo-5-methylphenol. **5b**: $R_f = 0.62$ (cyclohexane/EtOAc 6:1); $^1\text{H NMR}$ (400 MHz, CDCl₃): δ (ppm) = 2.29 (s, 3 H, CH₃), 5.10 (s, 2 H, CH₂), 5.12 (s, 2 H, CH₂), 6.83 (s, 1 H, 3-H or 6-H), 7.12 (s, 1 H, 6-H or 3-H), 7.30–7.43 (m, 10 H, 2 Ph); $^{13}\text{C NMR}$ (100 MHz, CDCl₃): δ (ppm) = 22.5 (CH₃), 71.7 (CH₂), 71.8 (CH₂), 115.5 (CH), 117.5 (C), 119.2 (CH), 127.5 (CH), 127.5 (CH), 128.0 (CH), 128.1 (CH), 128.7 (CH), 130.8 (C), 137.0 (C), 137.1 (C), 147.8 (C), 148.3 (C); IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3062 (vw), 3034 (vw), 2874 (vw), 1567 (vw), 1499 (w), 1453 (w), 1382 (w), 1369 (w), 1320

-
7. Alig, L.; Alsenz, J.; Andjelkovic, M.; Bendels, S.; Bénaudeau, A.; Bleicher, K.; Bourson, A.; David-Pierson, P.; Guba, W.; Hildbrand, S.; Kube, D.; Lübbers, T.; Mayweg, A. V.; Narquizian, R.; Neidhart, W.; Nettekoven, M.; Plancher, J.-M.; Rocha, C.; Rogers-Evans, M.; Röver, S.; Schneider, G.; Taylor, S.; Waldmeier, P. *J. Med. Chem.* **2008**, *51*, 2115–2127.
 8. da Silva Pinto, A. C.; Silva, L. F. R.; Cavalcanti, B. C.; Melo, M. R. S.; Chaves, F. C. M.; Lotufo, L. V. C.; de Moraes, M. O.; de Andrade-Neto, V. F.; Tadei, W. P.; Pessoa, C. O.; Ribeiro Vieirac, P. P.; Pohlit, A. M. *Eur. J. Med. Chem.* **2009**, *44*, 2731–2735.

(w), 1199 (w), 1157 (m), 1008 (w), 965 (w), 914 (w), 848 (w), 747 (w), 719 (w), 696 (m); MS (FAB), m/z (%) = 385 (15), 384 (35) [$C_{21}H_{19}^{81}BrO_2^+$], 383 (17), 382 (34) [$C_{21}H_{19}^{79}BrO_2^+$], 136 (29), 91 (100) [$C_7H_7^+$]; HRMS (FAB) found 382.0570. $C_{21}H_{19}^{79}BrO_2^+$ requires 382.0568. 2-Benzyloxy-4-bromo-5-methylphenol: R_f = 0.22 (hexanes/EtOAc 19:1); 1H NMR (300 MHz, $CDCl_3$): δ (ppm) = 2.29 (s, 3 H, CH_3), 5.05 (s, 4 H, $2\times CH_2$), 5.54 (br s, 1 H, OH), 6.82 (d, J = 10.8 Hz, 1 H, H-3 or H-6), 7.11 (d, J = 9.5 Hz, 1 H, H-6 or H-3), 7.34–7.45 (m, 5 H, Ph).

2-(4,5-Dibenzyloxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6b)

A solution of bis(benzylether) **5b** (100 mg, 0.261 mmol), KOAc (77 mg, 0.78 mmol), Pd(dppf) $Cl_2\cdot CH_2Cl_2$ (21 mg, 0.026 mmol), and bis(pinacolato)diboron (133 mg, 0.524 mmol) in anhydrous and degassed dioxane (1.4 mL) under an argon atmosphere was heated to 80 °C for 17 h. The mixture was filtered through a Celite pad and rinsed with EtOAc, concentrated at reduced pressure, and purified by column chromatography (silica gel, cyclohexane/toluene 1:1 → toluene → cyclohexane/EtOAc 4:1) to yield **6b** as a colorless liquid (62 mg, 0.144 mmol, 55%). R_f = 0.17 (cyclohexane/toluene 1:1); 1H NMR (300 MHz, $CDCl_3$): δ (ppm) = 1.35 (s, 12 H, $4\times Me$), 2.49 (s, 3 H, 2-Me), 5.16 (s, 2 H, CH_2) 5.18 (s, 2 H, CH_2), 6.79 (s, 1 H, 3-H or 6-H), 7.41 (s, 1 H, 6-H or 3-H), 7.27–7.54 (m, 10 H, 2 Ph); ^{13}C NMR (100 MHz, $CDCl_3$): δ (ppm) = 21.9 (CH_3), 25.0 ($4\times CH_3$), 70.8 (CH_2), 71.9 (CH_2), 83.4 ($2\times C$), 116.5 (CH), 122.9 (CH), 127.3 ($2\times CH$) 127.8 ($2\times CH$), 127.8 (CH), 127.8 (CH), 128.5 ($2\times CH$), 128.6 ($2\times CH$), 137.4 (C), 137.8 (C), 140.0 (C), 146.2 (C), 151.3 (C), signal of C-1 could not be detected (due to boron's quadrupole moment); IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 2972 (w), 1592 (m), 1512 (w), 1456 (w), 1407 (m), 1338 (m), 1300 (m), 1248 (m), 1139 (m), 1011 (m), 867 (m), 847 (m), 738 (m), 724 (m), 691 (m); MS (FAB): m/z (%) = 431 (17), 430 (48), 429 (14), 91 (100); HRMS (FAB) found 430.2316. $C_{27}H_{31}^{11}BO_4^+$ requires 430.2315.

1-(Benzyloxy)-3-bromo-5-methoxybenzene (9b)

BnBr (1.17 mL, 9.86 mmol) was added under an argon atmosphere to a solution of bromide **8** (1.61 g, 7.89 mmol) and K₂CO₃ (2.70 g, 19.7 mmol) in DMF/acetone 1:2 (60 mL). The mixture was stirred for 43 h at 80 °C and cooled to room temperature. To the brown suspension were added H₂O (100 mL) and 1 M HCl until pH 8. The aqueous layer was extracted with EtOAc (3 × 100 mL) and the combined organic layers were washed with brine (50 mL) and H₂O (100 mL), dried (MgSO₄), concentrated at reduced pressure, and purified by column chromatography (silica gel, hexanes/EtOAc 2:1) to yield **9b** as a colorless oil (2.27 g, 7.74 mmol, 98%). *R*_f = 0.32 (cyclohexane/EtOAc 50:1); ¹H NMR (300 MHz, CDCl₃): δ (ppm) = 3.77 (s, 3 H, Me), 5.02 (s, 2 H, CH₂), 6.47 (t, *J* = 2.1 Hz, 1 H, Ar-H), 6.69 (t, *J* = 1.8 Hz, 1 H, Ar-H), 6.77 (t, *J* = 1.9 Hz, 1 H, Ar-H), 7.33–7.44 (m, 5 H, Ph); ¹³C NMR (75 MHz, CDCl₃): δ (ppm) = 55.6 (CH₃), 70.4 (CH₂), 100.7 (CH), 110.3 (CH), 110.8 (CH), 123.1 (C), 127.7 (CH), 128.3 (CH), 128.8 (CH), 136.5 (C), 160.5 (C), 161.4 (C); IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2926 (w), 1595 (m), 1573 (m), 1425 (m), 1378 (m), 1329 (w), 1277 (m), 1192 (m), 1152 (s), 1055 (m), 1024 (m), 812 (m), 735 (m), 696 (m), 675 (m); MS (EI, 20 °C): *m/z* (%) = 294 (13) [C₁₄H₁₃⁸¹BrO₂⁺], 292 (14) [C₁₄H₁₃⁷⁹BrO₂⁺], 218 (40) [C₈H₈⁸¹BrO₂⁺], 216 (41) [C₈H₈⁷⁹BrO₂⁺], 108 (26), 107 (10), 105 (10), 92 (11), 91 (100) [C₇H₇⁺], 79 (13), 77 (18), 69 (21), 65 (10), 58 (19), 57 (14); HRMS (EI) found 292.0098. C₁₄H₁₃O₂⁷⁹Br⁺ requires 292.0099.

3',4,5-Tris(benzyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10b)

A solution of boronate **6b** (104 mg, 0.242 mmol), bromide **9b** (85 mg, 0.290 mmol), Cs₂CO₃ (315 mg, 0.967 mmol), Pd(OAc)₂ (2.7 mg, 12 μmol), and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos, 8.7 mg, 21 μmol) in degassed dioxane/H₂O 7:1 (9.3 mL) was heated for 18 h at 70 °C under an argon atmosphere. After cooling to room temperature H₂O (15 mL) was added and the aqueous phase was extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (75 mL), dried (Na₂SO₄), concentrated at

reduced pressure, and purified by column chromatography (silica gel, cyclohexane/EtOAc 50:1 → 15:1) to yield **10b** as a colorless, highly viscous product (111 mg, 0.215 mmol, 89%). $R_f = 0.32$ (cyclohexane/EtOAc 10:1); $^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm) = 2.16 (s, 3 H, 2-Me), 3.79 (s, 3 H, OMe), 5.05 (s, 2 H, CH_2), 5.13 (s, 2 H, CH_2), 5.18 (s, 2 H, CH_2), 6.42 (dd, $J = 2.2, 1.3$ Hz, 1 H, Ar-H), 6.47 (dd, $J = 2.2, 1.4$ Hz, 1 H, Ar-H), 6.52 (t, $J = 2.3$ Hz, 1 H, Ar-H), 6.84 (s, 1 H, Ar-H), 6.86 (s, 1 H, Ar-H), 7.29–7.50 (m, 15 H, 3 Ph); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ (ppm) = 20.0 (CH_3), 55.5 (CH_3), 70.2 (CH_2), 71.6 (CH_2), 71.8 (CH_2), 99.9 (CH), 108.1 (CH), 108.4 (CH), 117.2 (CH), 117.3 (CH), 127.5 (2 \times CH), 127.6 (2 \times CH), 127.6 (2 \times CH), 127.8 (CH), 127.9 (CH), 128.1 (CH), 128.5 (C), 128.5 (2 \times CH), 128.6 (2 \times CH), 128.7 (2 \times CH), 134.9 (C), 137.1 (C), 137.6 (2 \times C), 143.8 (C), 146.8 (C), 148.4 (C), 159.7 (C), 160.5 (C); IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 3031 (w), 2924 (w), 1590 (m), 1509 (m), 1453 (m), 1427 (w), 1378 (w), 1252 (m), 1190 (m), 1152 (m), 1065 (m), 1025 (m), 839 (m), 735 (m), 696 (m); MS (FAB): m/z (%) = 517 (11) [$\text{M}^+ + 1$], 516 (15) [M^+], 91 (100) [C_7H_7^+]; HRMS (FAB) found 516.2293. $\text{C}_{35}\text{H}_{32}\text{O}_4^+$ requires 516.2295.

5'-Methoxy-6-methyl-[1,1'-biphenyl]-3,3',4-triol; decarboxyaltenusin (1)

A mixture of benzyl-protected decarboxyaltenusin **10b** (100 mg, 0.194 mmol) and Pd/C (10%, 22 mg, 0.207 mmol) in THF (10 mL) in an autoclave with H_2 pressure (8 bar) was heated at 40 °C for 24 h, cooled, filtered over Celite, dried (Na_2SO_4), concentrated at reduced pressure, and purified by column chromatography (silica gel, hexanes/EtOAc 1:1) to yield **1** as a yellow oil (42 mg, 0.171 mmol, 88%). $R_f = 0.36$ (hexanes/EtOAc 1:1); $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ (ppm) = 2.05 (s, 3 H, 6-Me), 3.70 (s, 3 H, OMe), 6.20 (dd, $J = 2.1, 1.5$ Hz, 1 H, 6'-H), 6.22 (t, $J = 1.7$ Hz, 1 H, 2'-H), 6.25 (t, $J = 2.2$ Hz, 1 H, 4'-H), 6.55 (s, 1 H, 2-H), 6.60 (s, 1 H, 5-H), 8.72 (br s, 1 H, 3-OH), 8.78 (br s, 1 H, 4-OH), 9.37 (br s, 1 H, 3'-OH); $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO-}d_6$): δ (ppm) = 19.4 (CH_3 , OMe), 54.9 (CH_3 , 6-Me), 99.2 (CH, C-4'), 105.8 (CH, C-6'), 108.8 (CH, C-2'), 116.7 (CH, C-2), 117.5 (CH, C-5), 124.8 (C, C-6), 132.3 (C, C-1),

142.9 (C, C-1'), 143.6 (C, C-4), 144.3 (C, C-3), 158.0 (C, C-3'), 160.0 (C, C-5'); IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 3332 (br s), 2919 (m), 2849 (s), 1591 (m), 1519 (s), 1496 (s), 1427 (m); MS (EI, 140 °C): m/z (%) = 247 (17), 246 (100) [M^+], 245 (19), 197 (10), 73 (11), 69 (18) 57 (14), 55 (15); HRMS (FAB) found 246.0893. $\text{C}_{14}\text{H}_{14}\text{O}_4^+$ requires 246.0892.

Cell culture and cytotoxicity studies


HeLa cells (human cervix carcinoma cell line) cells were cultured in DMEM medium (*Gibco*) supplemented with 10% fetal bovine serum (FBS, *Gibco*) and 1% penicillin/streptavidin (*Gibco*) at 37 °C, 5% CO_2 . The cells were trypsinized (0.05% trypsin-EDTA, *Gibco*) and seeded into 96 well plates (toxicity assay) at 70% confluency for 24 h.

The medium was removed and the cells were treated with the indicated concentrations of decarboxyaltenuisin by diluting the DMSO stock solution in 100 μl DMEM supplemented with 10% FBS and penicillin/streptavidin as described above. The cells were incubated for 72 h at 37 °C, 5% CO_2 . For the negative control, the cell culture medium was replaced by medium. Eventually, the MTT assay was performed as describe in the manufacturer's manual (*Promega*). Prior to MTT assay, the positive control was treated with Triton X-100 (1%). After 3 h of incubation with the 15 μL of the MTT reagent the cells were lysed using the Stop Solution to release the blue-purple formazan. The cell viability was determined by measuring the absorbance of the resulting formazan at 595 nm using a multiwell plate reader (SpectraMax ID3, *Molecular Devices*, USA). The values were normalized against the positive and negative control. Experiments were performed with $n = 5$ and standard deviations were calculated using Student's t -test.


B. NMR Spectra

1. 1-Bromo-3,4-bis(*tert*-butyldimethylsilyloxy)-6-methylbenzene (5a)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




2. 2-[4,5-Bis(*tert*-butyldimethylsilyloxy)-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6a)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




3. 1-Bromo-3-(*tert*-butyldimethylsilyloxy)-5-methoxybenzene (9a)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




4. 3',4,5-Tris(*tert*-butyldimethylsilyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10a)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (400 MHz, CDCl_3)




5. 4,5-Dibenzoyloxy-1-bromo-2-methylbenzene (5b)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




6. 2-(4,5-Dibenzyloxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6b)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




7. 1-(Benzyloxy)-3-bromo-5-methoxybenzene (9b)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




8. 3',4,5-Tris(benzyloxy)-5'-methoxy-2-methyl-1,1'-biphenyl (10b)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




9. 5'-Methoxy-6-methyl-[1,1'-biphenyl]-3,3',4-triol; decarboxyaltenusin (1)


^1H NMR Spectrum (400 MHz, $\text{DMSO-}d_6$)




^{13}C NMR (100 MHz, $\text{DMSO-}d_6$)



HSQC (100 MHz, DMSO-*d*₆)



COSY (100 MHz, DMSO-*d*₆)



HMBC (100 MHz, DMSO-*d*₆)

